Stefan Norin
Fortune : 2 740 $ au 31/05/2026
Fortune : 2 740 $ au 31/05/2026
Stefan Norin currently works at Oncopeptides AB, as Chief Medical Officer from 2023.
Mr. Norin also formerly worked at Medivir AB, as Associate Director-Clinical Research & development from 2017 to 2019 and Karolinska University Hospital, as Head-Lymphosection.
Mr. Norin received his doctorate degree from Karolinska Institutet.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 19/03/2026 | 13 975 ( 0% ) | 2 740 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ONCOPEPTIDES AB | Directeur Technique/Scientifique/R&D | 01/09/2023 |
| Sociétés | Poste | Fin |
|---|---|---|
| MEDIVIR AB | Directeur Technique/Scientifique/R&D | 01/03/2019 |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Provides hospital services | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Medivir AB
Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Karolinska Institutet
Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oncopeptides AB
Oncopeptides AB Pharmaceuticals: MajorHealth Technology Develops chemotherapeutic pharmaceuticals of compounds for cancer treatment | Health Technology |
Karolinska University Hospital
Karolinska University Hospital Hospital/Nursing ManagementHealth Services Provides hospital services | Health Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national